Cancer of the pyriform fossa: hyperfractionated radiotherapy as a primary treatment modality.
Carcinoma of the pyriform fossa carries one of the worst prognoses of all head and neck cancers. A prospective trial was set up to study the efficacy of hyperfractionated radiotherapy as a primary treatment modality in the management of these patients. Seventeen patients entered the trial and were followed for up to 3 years. Results for local control, regional control and survival compare favourably with patients treated primarily with surgery with or without radiotherapy. Hyperfractionated radiotherapy offers a logical and standardized approach to the management of this tumour and reduces the significant morbidity associated with the use of surgery as a primary treatment.
Conlon
B J
BJ
Department of Otolaryngology Head and Neck Surgery, Mater Hospital, Dublin, Ireland.
Walsh
M
M
McShane
D
D
Corcoran
N
N
Moriarty
M
M
Healy
J B
JB
Fraser
I
I
O'Dwyer
T P
TP
D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D019583:Dose Fractionation, Radiation; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D006801:Humans; D009364:Neoplasm Recurrence, Local; D011446:Prospective Studies; D015996:Survival Rate